Generic Name and Formulations:
Nepafenac 0.1%, oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for NEVANAC:
Post-operative pain and inflammation following cataract surgery.
≥10yrs: 1 drop in affected eye(s) 3 times daily starting one day before surgery, continued on day of surgery, and through first 2 weeks post-op.
<10yrs: not established.
Bleeding tendencies. May delay wound healing. Complicated/repeat ocular surgeries. Corneal defects/denervation. Ocular surface diseases. Rheumatoid arthritis. Diabetes. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Risk of corneal adverse events may be increased if used more than 24 hours before surgery, or beyond 14 days post-op. Contact lenses (remove during therapy). Pregnancy (Cat.C; avoid during 3rd trimester). Nursing mothers.
Caution with concomitant medications that may prolong bleeding time. Increased potential for healing problems with concomitant topical steroids.
Ocular effects (eg, capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, sticky sensation, edema, dry eye, lid margin crusting, discomfort, hyperemia, pain, pruritus, photophobia, tearing, vitreous detachment), headache, hypertension, GI upset, sinusitis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations